Loading clinical trials...
Loading clinical trials...
A Multicenter, Single Sequence, Open-label Study to Assess the Tolerability, Safety, and Efficacy of 2 Weeks Oral AEB071 300 mg Twice Daily, Followed by 6 Weeks AEB071 200 mg Twice Daily in the Treatment of Patients With Macular Edema Associated With Non-infectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis
Conditions
Interventions
AEB071
Locations
13
United States
University of Southern California Doheny Eye Institute
Los Angeles, California, United States
University of California
San Francisco, California, United States
Colorado Retina Associates
Denver, Colorado, United States
University of Miami Miller School of Medicine; Anne Bates Leach Eye Hosptial;Bascom Palmer Eye Institute
Miami, Florida, United States
University of South Florida, Eye Institute
Tampa, Florida, United States
Emory University
Atlanta, Georgia, United States
Start Date
July 1, 2008
Primary Completion Date
October 1, 2009
Last Updated
December 22, 2020
NCT07218770
NCT06974162
NCT07145008
NCT05486468
NCT05200715
NCT02706704
Lead Sponsor
Novartis
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions